Schering extends deal with NeXstar

Article

German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased

German contrast agent firm Schering has extended its ongoing R&Dcollaboration with pharmaceutical developer NeXstar of Boulder,CO, for the development of in vivo imaging agents using NeXstar'sSelex combinatorial chemistry process. Schering increased itsresearch payments to NeXstar to $2.4 million a year from $1 milliona year as part of the deal.

Under the collaboration, NeXstar is using the Selex processto develop aptamers, which are short stretches of modified DNAor RNA that can bind to diagnostic targets in the body. Thesetargets can be identified by imaging modalities, and Scheringhas specified several cardiac and oncology applications it isinterested in pursuing.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Subscribe Now!
Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
Radiology Partners Launches Enterprise Imaging Platform MosaicOS

Radiology Partners Launches Enterprise Imaging Platform MosaicOS

Jeff Hall
July 15th 2025
Article

A cloud-based and AI-native radiology operating system, MosaicOS reportedly enables the combination of diagnostic AI tools and workflow enhancements into one scalable platform.

The Reading Room Podcast: Current Insights on Recent Research About Radiation-Induced Cancers with CT Scans, Part 2

The Reading Room Podcast: Current Insights on Recent Research About Radiation-Induced Cancers with CT Scans, Part 2

Jeff Hall
May 5th 2025
Podcast

In a second part of a new podcast episode on recently published research on projected radiation-induced cancers from computed tomography (CT) scans, Mahadevappa Mahesh, MS, Ph.D., and Joseph Cavallo, M.D., offer current perspectives on cardiac CT dosing, AI advances and the importance of teamwork in ensuring appropriate dosing for CT.

Study: Adjunctive AI Provides Over 18 Percent Higher Lesion-Level Sensitivity on Prostate MRI

Study: Adjunctive AI Provides Over 18 Percent Higher Lesion-Level Sensitivity on Prostate MRI

Jeff Hall
July 15th 2025
Article

Emerging research revealed significantly enhanced sensitivity for prostate cancer detection with adjunctive and stand-alone use of AI.

The Reading Room Podcast: Current Insights on Recent Research About Radiation-Induced Cancers with CT Scans, Part 1

The Reading Room Podcast: Current Insights on Recent Research About Radiation-Induced Cancers with CT Scans, Part 1

Jeff Hall
May 2nd 2025
Podcast

In a new podcast, Mahadevappa Mahesh, MS, Ph.D., and Joseph Cavallo, M.D., share their perspectives on recently published research looking at projections for future radiation-induced cancers from computed tomography (CT) scans.

Living on Borrowed (or Bought) Radiological Time

Living on Borrowed (or Bought) Radiological Time

Eric Postal, MD
July 14th 2025
Article

How does onboarding factor into radiologist compensation?

CCTA Study: Plaque Burden Offers No Prognostic Benefit for Predicting Cardiac Events in Patients with Acute Chest Pain

CCTA Study: Plaque Burden Offers No Prognostic Benefit for Predicting Cardiac Events in Patients with Acute Chest Pain

Jeff Hall
July 11th 2025
Article

For patients who had coronary CTA for acute chest pain, emerging research found no significant association between plaque burden grades with CAD-RADS 2.0 and cardiac events.

© 2025 MJH Life Sciences

All rights reserved.